SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors react to a recent SEC filing regarding executive change-of-control agreements, which many in the community interpret as a strategic setup for a potential buyout. The conversation is heavily focused on the anticipation of the final 80th event in the REGAL Phase 3 trial, with retail investors and institutions monitoring extreme short interest and high borrowing costs as catalysts for a potential squeeze.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant market activity driven by strong federal support, including a major government initiative for quantum sensing and the company's confirmed inclusion in the Russell index. While community members debate whether recent price fluctuations are due to coordinated market manipulation or institutional rebalancing, the primary focus remains on the stock's long-term potential as a strategic player in the quantum sector.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant selling pressure as investors scrutinize the company's leveraged Bitcoin-heavy business model amid ongoing market declines. The community is deeply polarized, with active debates centered on fears of forced liquidation or bankruptcy versus contrarian views that the current price represents a generational accumulation opportunity.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors weigh the stock's recent pullback against upcoming catalysts, including the June EMA regulatory decision and the July 1 implementation of a permanent J-code for Yartemlea. The community is actively discussing the stock's valuation, questioning management's communication strategy, and debating the potential impact of short interest versus the company's long-term commercial potential.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector, represented by the VanEck Semiconductor ETF (SMH), is currently facing a sharp period of volatility and selling pressure as investors rotate out of the historically crowded AI trade. Community discourse is polarized, with many traders actively scaling into short positions and calling for a deeper correction while long-term investors debate whether this is a temporary pullback or the beginning of a larger cyclical unwind.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense downward pressure as investors express frustration over a multi-year slump, growing competition from emerging athletic brands, and a series of analyst downgrades ahead of the next earnings report. While some in the community argue the stock is a deep-value play due to its iconic brand status and potential for a turnaround, others are actively betting against it, citing concerns over stagnant innovation and deteriorating margins.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is drawing significant investor attention following its announcement of a seven-billion-dollar all-stock acquisition of Synaptics, a move intended to bolster its leadership in physical AI, power efficiency, and edge computing. While the strategic consolidation is viewed by many as a vital play for long-term dominance in AI-enabled infrastructure, the market is actively debating the deal's valuation and the short-term pressure on share price resulting from the merger terms.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending as investors react to the company's recent move to replace high-interest secured debt with $250 million in low-interest convertible notes, a strategic financial restructuring that analysts view as a sign of institutional confidence. While some retail investors initially expressed concerns over potential dilution, the community is focused on the debt-free balance sheet improvements, the protection provided by capped calls, and the bolstered cash position for advancing their Ibtrozi and Safusidenib pipelines.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending as the market aggressively reprices former Bitcoin miners into critical AI and high-performance computing infrastructure plays, fueled by a massive, multi-billion dollar colocation contract with CoreWeave. The community is focused on the stock's transition toward AI-driven revenue stability, monitoring institutional accumulation and potential upcoming contract announcements that could further validate its role as a key player in the AI compute super-cycle.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is generating buzz as retail investors speculate on potential M&A activity, fueled by high call-option volume and unconfirmed buyout rumors. Despite this momentum, many community members remain frustrated by the stock's long-term volatility and perceived institutional manipulation, while others emphasize the need for technical catalysts like resolving manufacturing issues to drive a sustained breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

Denali to Sell Priority Review Voucher for $195M Cash Boost

DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos...

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails 

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said. 


Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

Key PointsADAR1 added 1,819,339 Denali Therapeutics shares; estimated trade value is $36.20 million (based on average prices from the first quarter of 2026...

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.

Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'

Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.read more...

Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval

Key PointsAcquired 254,857 shares of Denali Therapeutics; estimated transaction value $5.07 million (based on quarterly average price...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

Neutral Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Current Price	$24.73
Prev Close	$24.82
Open	$24.83
Dividend Yield	0.00%
50-Day Moving Average	$20.40
Beta	1.66
Avg. Volume	1.9M
PE Ratio	-8.58

52-Week High	$25.97
52-Week Low	$12.58
Market Capitalization	$3.94B
EPS (Annual)	-$2.97
Price to Book	4.24
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNLIDenali Therapeutics Inc

Latest DNLI News